Cabaletta Bio (CABA) vs Ocugen (OCGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cabaletta Bio (CABA) has outperformed Ocugen (OCGN) over the past year, losing 15.1% versus a loss of 43.2%. Over five years, CABA leads with a -83.9% price change compared with -88.5% for OCGN. Ocugen is the larger company by market cap ($339.1 million vs $334.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CABA | OCGN |
|---|---|---|
| Share price | $1.97 | $1.00 |
| Market cap | $334.00M | $339.11M |
| 1-day change | -2.48% | -3.85% |
| YTD return | -10.05% | -25.93% |
| 1-year return | -15.09% | -43.18% |
| 5-year return | -83.93% | -88.45% |
| EPS (TTM) | $-1.51 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.23 | $2.73 |
| 52-week low | $1.83 | $0.97 |
| Distance from 52-week high | -53.43% | -63.30% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +572.59% | +1117.00% |
| Average volume | 4.71M | 5.82M |
| Shares outstanding | 169.55M | 339.11M |
| Employees | 154 | 116 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CABA has outperformed OCGN by 28.1 percentage points over the past year.
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Healthcare · Biotechnology · 154 employees
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Healthcare · Biotechnology · 116 employees
CABA vs OCGN FAQ
Which is bigger, Cabaletta Bio or Ocugen?
Ocugen (OCGN) is larger, with a market capitalization of $339.11M compared with $334.00M for Cabaletta Bio (CABA).
Which stock has performed better over the past year, CABA or OCGN?
CABA returned -15.09% over the past 12 months, compared with -43.18% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Cabaletta Bio and Ocugen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.